pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Eli Lilly and Co · news · pharmadog
← back to Eli Lilly and Co
News mentioning Eli Lilly and Co
184
stories
2d
As part of sales reorganization, Novo will cut 215 employees at US HQ
biospace
2d
Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
biopharma dive
4d
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
biopharma dive
4d
8 companies hiring in North Carolina now
biospace
4d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
5d
Isomorphic Labs breaks biotech VC fundraising record with $5B series C
biospace
5d
AI drugmaker Isomorphic restocks with $5B fundraise
biopharma dive
5d
Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
biospace
5d
Isomorphic Labs raises $5B series C months after $2.1B round
fiercebiotech
6d
Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
biospace
6d
STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
stat
6d
Big-name investors pour $100M into DNA therapeutics developer Seawolf
biopharma dive
6d
Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTech
fiercebiotech
6d
Flagship commits £100M to set up AI-focused biotech incubation outpost in London
fiercebiotech
9d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
9d
The promise of molecular gates and what comes next
fiercebiotech
9d
STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
stat
10d
Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact
fiercebiotech
10d
Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launch
fiercebiotech
11d
Drug price hikes in Germany could push US costs higher, study says
biopharma dive
11d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
12d
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
biospace
12d
BioSpace 2027 Best Places to Work shines light on most admired employers
biospace
12d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
12d
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
biospace
13d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
16d
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
biopharma dive
17d
T-time: British biotech pours $133M into the pot for bispecifics
biospace
17d
MetaVia sees GLP-1 shed liver fat and body weight in phase 1, takes aim at specific liver disease
fiercebiotech
17d
The top 12 companies hiring in biopharma now
biospace
← prev
page 1 of 7
next →